[Survival of patients with pulmonary arterial hypertension after the advent of specific pulmonary vasodilator therapies].

Abstract

BACKGROUND Pulmonary arterial hypertension (PAH) is a rare and progressive disease. Long-term survival remains poor despite of advances in specific vasodilator therapy. AIM To describe the survival rate in a cohort of PAH patients in two referral centers in Chile. PATIENTS AND METHODS One hundred fifteen patients aged 43 ± 15.6 years (85% females) with PAH qualified for this study. Their median pulmonary artery pressure was 55.4 ± 14 mmHg and their six minutes walking capacity was 368 ± 119 m. They were followed for 58 ± 0.4 months and their actual survival rates were compared with the estimated survival using the equation proposed by the French registry of PAH. RESULTS One, two and three year survival rates were 97, 94 and 89%, respectively. The observed survival rates were greater than the estimated survival. CONCLUSIONS The improvement in survival rates observed in this cohort of patients is similar to what has been described in literature.

DOI: 10.4067/S0034-98872016000700002

Cite this paper

@article{Herrera2016SurvivalOP, title={[Survival of patients with pulmonary arterial hypertension after the advent of specific pulmonary vasodilator therapies].}, author={Sebastian D Herrera and Luigi Gabrielli and Alejandro Paredes and Rodrigo Retamales Saavedra and Mar{\'i}a Paz Ocaranza and Pablo Sep{\'u}lveda and Hern{\'a}n Donoso and Leonel L{\'o}pez and Hugo E. Verdejo and Fernando R Baraona and Pablo F. Castro}, journal={Revista medica de Chile}, year={2016}, volume={144 7}, pages={829-36} }